ABSTRACT
Introduction An emerging body of epidemiological evidence links a history of exposure to sexual and physical abuse or assault with an increased risk of developing cardiovascular disease. Understanding adverse physical health outcomes including heart failure (HF) in persons exposed to sexual and physical abuse is of particular importance to help improve multidisciplinary approaches to mental and physical wellbeing, including cardiovascular management, among vulnerable populations.
Methods This case-control study was performed at a tertiary hospital in metropolitan South Australia. At index HF admission 12 consecutive female patients with exposure to sexual and physical abuse or assault were identified from the trauma module of a structured psychiatric interview. Index admission data were classified into HF phenotype and aetiology using the criteria and definitions of the European Society of Cardiology. The presentation profile at index HF admission was compared to 12 gender and age-matched comparators.
Results The clinical characteristics at index admission showed that most patients presented with pulmonary rales, peripheral oedema, and pulmonary congestion (67-75%), with diuretics the most common intervention (75%). By comparison to the non-exposed group, we observed differences between groups in HF severity determined by New York Heart Association class, diastolic blood pressure (BP), and heart rate (HR) but not systolic BP, saturation of peripheral oxygen (Sp02) or HF phenotypes. There were no differences in troponin, creatinine, sodium, admission use of inotropes, vasodilators or diuretics, post-traumatic stress disorder or comorbidities between the exposed patients and age-matched female controls.
Conclusion Women with a history of experiencing sexual and physical abuse or assault presented with a unique HF admission profile characterised by lower BP and HR. The findings support previous work suggesting that persons experiencing sexual and physical abuse or assault have blunted cardiovascular reactivity to stressors such as hospital admission.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Human Research Ethics Committee from the Queen Elizabeth and Lyell McEwin hospitals TQEHLMH/188
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Author/funding disclosures: none to declare
Data Availability
Due to the potential for re-identifying sensitive information about the exposure of interest, only general descriptive information is provided for each case. Data is not available due to ethics restraints.
